calderasib
Sponsor Merck & CO INC. · listed as MRK
calderasib is a drug asset sponsored by Merck & CO INC., listed as MRK. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jan 24, 2028 (day precision, medium confidence), tied to trial NCT06345729. That trial is in Phase 3 and currently recruiting, studying Non-small Cell Lung Cancer. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for calderasib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06345729 catalyst | Phase 3 | Recruiting | 2028-01-24 | Experimental | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer |
| NCT06997497 | Phase 3 | Recruiting | 2029-03-28 | Experimental | Merck Sharp & Dohme LLC | Colon Adenocarcinoma; Rectal Adenocarcinoma |
| NCT07190248 | Phase 3 | Recruiting | 2029-12-07 | Experimental | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer |
| NCT07554339 | Phase 3 | Recruiting | 2032-12-15 | Experimental | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer |
| NCT07431827 | Phase 3 | Recruiting | 2039-10-26 | Experimental | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More MRK catalysts